MONTREAL, QUEBEC -- (MARKET WIRE) -- March 27, 2007 -- Ambrilia Biopharma Inc. (TSX: AMB), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, announced today its fiscal 2006 results and provided an update on its development programs.
